logo

For the Inventor, By the Inventor

Coventry, RI, United States of America

Rhodes Technologies


USPTO Granted Patents = 47

% Expired Patents = 4.3



Forward Citations = 109

Loading Chart...
Loading Chart...

30 inventors (with patents filed for the assignee):

goldMedal Robert J Kupper (16 out of 31 patents)

silverMedal Helge Alfred Reisch (15 out of 15 patents)

bronzeMedal Joshua Robert Giguere (15 out of 17 patents)

4.  Lonn S Rider (13 out of 19 patents)

5.  Donald Kyle (10 out of 341 patents)

6.  Robert Chapman (10 out of 18 patents)

7.  Qi Hong (10 out of 20 patents)

8.  Keith Edward McCarthy (10 out of 10 patents)

9.  Sergio Sandoval (7 out of 7 patents)

10.  Jake Larry Stymiest (7 out of 7 patents)

11.  Raymond C Glowaky (6 out of 7 patents)

12.  Erik Wayne Kataisto (6 out of 6 patents)

13.  C Frederick M Huntley (6 out of 6 patents)

14.  Ping Chang (6 out of 6 patents)

15.  Archana Sharma (5 out of 5 patents)


Core Competencies:
Cannabinoid Compositions
Oxycodone Hydrochloride
Opioid Ketal Compounds
Pharmaceutical Formulations
Ophthalmic Treatments
Dosage Forms
Nalmefene Hydrochloride
Buprenorphine Acetate Salt
Stability Enhancement
N-allyl Compounds
Oxymorphone Synthesis
Dronabinol Compositions

47 patents:

1. 12702690 - Cannabinoid compositions and dosage forms for intranasal or inhalational delivery (2026-08-11),
2. 12668596 - Process for crystallizing nalmefene hydrochloride (2026-06-30),
3. 12419896 - Compositions and dosage forms for oral delivery (2025-09-23),
4. 12396948 - Pharmaceutical compositions for the treatment of ophthalmic conditions (2025-08-26),
5. 12060361 - Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone (2024-08-13),
6. 12011430 - Compositions and dosage forms for oral delivery (2024-06-18),
7. 11845759 - Opioid compounds and uses thereof (2023-12-19),
8. 11786463 - Pharmaceutical compositions for the treatment of ophthalmic conditions (2023-10-17),
9. 11773107 - Opioid ketal compounds and uses thereof (2023-10-03),
10. 11731979 - Opioid ketal compounds and uses thereof (2023-08-22),
11. 11390627 - Process for improved opioid synthesis (2022-07-19),
12. 11384091 - Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone (2022-07-12),
13. 11130765 - Opioid ketal compounds and uses thereof (2021-09-28),
14. 11091496 - Opioid ketal compounds and uses thereof (2021-08-17),
15. 10988480 - Opioid ketal compounds and uses thereof (2021-04-27),
Company Overview
Rhodes Technologies, based in Coventry, RI, specializes in the development and manufacturing of innovative pharmaceutical compositions. The company focuses on oral delivery systems and is particularly noted for its work in addressing ophthalmic conditions and formulating opioid compounds. Their expertise includes the synthesis of oxycodone and the stabilization of dronabinol, alongside research into buprenorphine acetate salt and N-allyl compounds. Rhodes Technologies is committed to advancing therapeutic solutions in the pharmaceutical landscape.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

47 Patents

#1 in Coventry, RI

#36 in Rhode Island

#7,430 in US

#14,803 in the World

Coventry, RI (US)
Coventry, RI, United States of America

Rhodes Technologies

Forward Citations = 109

30 inventors:

goldMedal Robert J Kupper (16 out of 31 patents)

silverMedal Helge Alfred Reisch (15 out of 15 patents)

bronzeMedal Joshua Robert Giguere (15 out of 17 patents)

4.  Lonn S Rider (13 out of 19 patents)

5.  Donald Kyle (10 out of 341 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Rhodes Technologies. Retrieved from https://idiyas.com/company/rhodes-technologies

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…